HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,836,781 | +4.2% | 440,754 | -1.6% | 0.02% | +11.1% |
| Q2 2023 | $16,158,638 | +91145.3% | 447,980 | -3.4% | 0.02% | -18.2% |
| Q1 2023 | $17,709 | -31.9% | 463,708 | +1.4% | 0.02% | -37.1% |
| Q4 2022 | $26,014 | -99.9% | 457,186 | +1.6% | 0.04% | +29.6% |
| Q3 2022 | $17,797,000 | -7.3% | 450,092 | +3.1% | 0.03% | -3.6% |
| Q2 2022 | $19,203,000 | +15.8% | 436,442 | +5.0% | 0.03% | +33.3% |
| Q1 2022 | $16,582,000 | -0.7% | 415,798 | +0.1% | 0.02% | +5.0% |
| Q4 2021 | $16,704,000 | -1.7% | 415,414 | -0.5% | 0.02% | -13.0% |
| Q3 2021 | $16,989,000 | -7.0% | 417,618 | +3.8% | 0.02% | -4.2% |
| Q2 2021 | $18,262,000 | +13.8% | 402,167 | +4.5% | 0.02% | +9.1% |
| Q1 2021 | $16,044,000 | -7.4% | 384,849 | -5.1% | 0.02% | -8.3% |
| Q4 2020 | $17,323,000 | +233.9% | 405,606 | +105.5% | 0.02% | +200.0% |
| Q3 2020 | $5,188,000 | -25.1% | 197,402 | -23.6% | 0.01% | -33.3% |
| Q2 2020 | $6,929,000 | +71.9% | 258,464 | +15.4% | 0.01% | +50.0% |
| Q1 2020 | $4,030,000 | -0.3% | 224,036 | -1.8% | 0.01% | +14.3% |
| Q4 2019 | $4,044,000 | +20.0% | 228,077 | +5.0% | 0.01% | +16.7% |
| Q3 2019 | $3,369,000 | -8.7% | 217,208 | +1.1% | 0.01% | -14.3% |
| Q2 2019 | $3,692,000 | +29.1% | 214,906 | +21.0% | 0.01% | +16.7% |
| Q1 2019 | $2,859,000 | +9.1% | 177,570 | -0.9% | 0.01% | 0.0% |
| Q4 2018 | $2,620,000 | +17.1% | 179,099 | +45.4% | 0.01% | +50.0% |
| Q3 2018 | $2,238,000 | -0.1% | 123,163 | -7.2% | 0.00% | -20.0% |
| Q2 2018 | $2,240,000 | -7.9% | 132,784 | +7.0% | 0.01% | 0.0% |
| Q1 2018 | $2,431,000 | -5.4% | 124,081 | -2.2% | 0.01% | 0.0% |
| Q4 2017 | $2,569,000 | +3.2% | 126,811 | -11.5% | 0.01% | 0.0% |
| Q3 2017 | $2,490,000 | +44.4% | 143,342 | +6.6% | 0.01% | +25.0% |
| Q2 2017 | $1,724,000 | -3.1% | 134,439 | -2.1% | 0.00% | 0.0% |
| Q1 2017 | $1,780,000 | +39.4% | 137,360 | +6.3% | 0.00% | +33.3% |
| Q4 2016 | $1,277,000 | -12.2% | 129,239 | +7.4% | 0.00% | -25.0% |
| Q3 2016 | $1,454,000 | +36.3% | 120,356 | -2.7% | 0.00% | +33.3% |
| Q2 2016 | $1,067,000 | +2.4% | 123,650 | +12.4% | 0.00% | 0.0% |
| Q1 2016 | $1,042,000 | -45.3% | 110,029 | +0.1% | 0.00% | -50.0% |
| Q4 2015 | $1,904,000 | +38.8% | 109,883 | +7.5% | 0.01% | +20.0% |
| Q3 2015 | $1,372,000 | -39.6% | 102,188 | +1.5% | 0.01% | -28.6% |
| Q2 2015 | $2,272,000 | +54.3% | 100,638 | -2.3% | 0.01% | +75.0% |
| Q1 2015 | $1,472,000 | +76.7% | 103,058 | +19.4% | 0.00% | +100.0% |
| Q4 2014 | $833,000 | +2.6% | 86,318 | -3.3% | 0.00% | 0.0% |
| Q3 2014 | $812,000 | -10.2% | 89,238 | -2.5% | 0.00% | -33.3% |
| Q2 2014 | $904,000 | -17.7% | 91,483 | +5.7% | 0.00% | 0.0% |
| Q1 2014 | $1,099,000 | -17.5% | 86,574 | -2.6% | 0.00% | -25.0% |
| Q4 2013 | $1,332,000 | +39.2% | 88,884 | +2.5% | 0.00% | +33.3% |
| Q3 2013 | $957,000 | +37.7% | 86,714 | -0.9% | 0.00% | +50.0% |
| Q2 2013 | $695,000 | – | 87,508 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |